logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Aileron Therapeutics, Inc.


USPTO Granted Patents = 44

% Expired Patents = 50.0



Trademarks = 1

Forward Citations = 793

Loading Chart...
Loading Chart...

36 inventors (with patents filed for the assignee):

goldMedal Huw M Nash (24 out of 35 patents)

silverMedal Noriyuki Kawahata (19 out of 19 patents)

bronzeMedal Vincent Guerlavais (17 out of 22 patents)

4.  David Allen Annis (11 out of 13 patents)

5.  Tomi K Sawyer (10 out of 35 patents)

6.  Eric Feyfant (6 out of 10 patents)

7.  Carl Elkin (5 out of 7 patents)

8.  Bradford Graves (4 out of 12 patents)

9.  Krzysztof Darlak (4 out of 4 patents)

10.  Rosana Kapeller-Libermann (4 out of 58 patents)

11.  Manuel Aivado (3 out of 3 patents)

12.  Karen Olson (3 out of 3 patents)

13.  Sameer Ahmed Athamneh (3 out of 3 patents)

14.  Manoj Samant (3 out of 3 patents)

15.  Christopher Leitheiser (2 out of 3 patents)


Core Competencies:
Peptidomimetic Macrocycles
Disubstituted Amino Acids
Triazole Macrocycle Systems
Bis-Sulfhydryl Macrocyclization
Stabilized P53 Peptides
HIF1alpha Regulation
Thioether-Crosslinked Macrocycles
Purified Polypeptide Compositions
Therapeutic Macrocycles
Internally Constrained Peptides

44 patents:

1. 11091522 - Peptidomimetic macrocycles and uses thereof (2021-08-17),
2. 11008366 - Peptidomimetic macrocycles (2021-05-18),
3. 10967042 - Peptidomimetic macrocycles (2021-04-06),
4. 10905739 - Peptidomimetic macrocycles and formulations thereof (2021-02-02),
5. 10703780 - Peptidomimetic macrocycles (2020-07-07),
6. 10669230 - Disubstituted amino acids and methods of preparation and use thereof (2020-06-02),
7. 10471120 - Peptidomimetic macrocycles and uses thereof (2019-11-12),
8. 10328117 - Bis-sulfhydryl macrocyclization systems (2019-06-25),
9. 10308699 - Peptidomimetic macrocycles (2019-06-04),
10. 10300109 - Peptidomimetic macrocycles (2019-05-28),
11. 10253067 - Peptidomimetic macrocycles and uses thereof (2019-04-09),
12. 10246491 - Peptidomimetic macrocycles and use thereof in regulating HIF1alpha (2019-04-02),
13. 10227380 - Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles (2019-03-12),
14. 10213477 - Peptidomimetic macrocycles (2019-02-26),
15. 10202431 - Stabilized P53 peptides and uses thereof (2019-02-12),
Company Overview
Aileron Therapeutics, Inc., based in Cambridge, MA, specializes in the development of innovative therapeutic macrocycles. The company focuses on peptidomimetic macrocycles and advanced polypeptide compositions, leveraging unique technologies such as bis-sulfhydryl macrocyclization systems and triazole macrocycle systems. Aileron's research aims to address critical biological challenges, including the regulation of HIF1alpha and the stabilization of P53 peptides, contributing to the advancement of targeted therapies in oncology and other therapeutic areas.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Aileron Therapeutics, Inc. USPTO Patent Assignee Logo
44 Patents

#65 in Cambridge, MA

#456 in Massachusetts

#7,956 in US

#15,756 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Aileron Therapeutics, Inc.

Forward Citations = 793

36 inventors:

goldMedal Huw M Nash (24 out of 35 patents)

silverMedal Noriyuki Kawahata (19 out of 19 patents)

bronzeMedal Vincent Guerlavais (17 out of 22 patents)

4.  David Allen Annis (11 out of 13 patents)

5.  Tomi K Sawyer (10 out of 35 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Aileron Therapeutics, Inc.. Retrieved from https://idiyas.com/company/aileron-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…